Agonist replacement therapy for cocaine dependence: a translational review

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, Rockville, MD, USA (2009).
  Google Scholar
• 2  Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) Highlights – 2007 National Admissions to Substance Abuse Treatment Services. Office of Applied Studies, Rockville, MD, USA (2009).
  Google Scholar
• 3  European Monitoring Centre for Drugs and Drug Addiction. 2009 Annual report on the state of the drugs problem in Europe. Publications Office of the European Union, Luxembourg (2009).
  Google Scholar
• 4  Chen K, Scheier LM, Kandel DB. Effects of chronic cocaine use on physical health: a prospective study in a general population sample. Drug Alcohol Depend.43,23–37 (1996).
  Medline CASGoogle Scholar
• 5  Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation122,2558–2569 (2010).
  MedlineGoogle Scholar
• 6  Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: National Findings. Office of Applied Studies: Rockville, MD, USA (2010).
  Google Scholar
• 7  Rounsaville BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gawin F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch. Gen. Psychiatry48,43–51 (1991).
  Medline CASGoogle Scholar
• 8  Van Tieu H, Koblin BA. HIV, alcohol and noninjection drug use. Curr. Opin HIV AIDS4,314–318 (2009).
  MedlineGoogle Scholar
• 9  Covi L, Hess JM, Schroeder JR, Preston KL. A dose response study of cognitive behavioral therapy in cocaine abusers. J. Subst. Abuse Treat.23,191–197 (2002).
  MedlineGoogle Scholar
• 10  McKee SA, Carroll KM, Sinha R et al. Enhancing brief cognitive–behavioral therapy with motivational enhancement techniques in cocaine users. Drug Alcohol Depend.91(1),97–101 (2007).
  MedlineGoogle Scholar
• 11  Higgins ST, Heil SH, Lussier JP. Clinical implications of reinforcement as a determinant of substance use disorders. Ann. Rev. Psychol.55,431–461 (2004).
  MedlineGoogle Scholar
• 12  Vocci FJ, Montoya ID. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Curr. Opin Psychiatry22(3),263–268 (2009).
  MedlineGoogle Scholar
• 13  de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M. Pharmacological treatment of cocaine dependence: a systematic review. Addiction97(8),931–949 (2002).
  MedlineGoogle Scholar
• 14  Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr. Opin Psychiatry18,265–270 (2005).
  MedlineGoogle Scholar
• 15  Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs64,1547–1573 (2004).
  Medline CASGoogle Scholar
• 16  Platt DM, Rowlett JK, Spealman RD. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology163,265–282 (2002).
  Medline CASGoogle Scholar
• 17  Cornish JW, Metzger D, Woody GE et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J. Subst. Abuse Treat.14(6),529–534 (1997).
  Medline CASGoogle Scholar
• 18  Rea F, Bell JR, Young MR, Mattick RP. A randomized, controlled trial of low dose naltrexone for the treatment of opioid dependence. Drug Alcohol Depend.75,79–88 (2004).
  Medline CASGoogle Scholar
• 19  Rose JE, Behm FM. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob. Res.6,523–532 (2004).
  MedlineGoogle Scholar
• 20  Grabowski J, Rhoades H, Stotts A et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology29,969–981 (2004).▪ This elegant pair of clinical trials demonstrated that agonist-replacement is likely a more successful strategy for managing cocaine-use disorders than antagonist pharmacotherapy.
  Medline CASGoogle Scholar
• 21  Karila L, Raynaud M, Aubin HJ et al. Pharmacological treatments for cocaine dependence: is there something new? Curr. Pharm. Des.17(14),1359–1368 (2011).
  Medline CASGoogle Scholar
• 22  Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res.102,227–233 (2001).
  Medline CASGoogle Scholar
• 23  Grabowski J, Rhoades H, Silverman P et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J. Clin. Psychopharmacol.20,305–310 (2000).
  Medline CASGoogle Scholar
• 24  Kampman KM, Pettinati H, Lynch KG, Sparkman T, O’Brien CP. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend.70,265–273 (2003).
  Medline CASGoogle Scholar
• 25  Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict. Behav.29,1439–1464 (2004).
  MedlineGoogle Scholar
• 26  Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend.101(1–2),34–41, (2009).▪▪ This clinical trial demonstrated that maintenance on sustained-release methamphetamine substantially decreases cocaine use, which was verified by urine toxicology testing.
  Medline CASGoogle Scholar
• 27  Henningfield JE. Nicotine medications for smoking cessation. N. Engl. J. Med.333,1196–1203 (1995).
  Medline CASGoogle Scholar
• 28  Ling W, Rawson RA, Compton MA. Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. J. Psychoactive Drugs26,119–128 (1994).
  Medline CASGoogle Scholar
• 29  Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev.CD000146 (2004).
  MedlineGoogle Scholar
• 30  Sofuoglu M, Kosten TR. Pharmacologic management of relapse prevention in addictive disorders. Psychiatr. Clin. North. Am.27,627–648 (2004).
  MedlineGoogle Scholar
• 31  Rush CR, Kollins SH, Pazzaglia PJ. Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion and triazolam in D-amphetamine-trained humans. Exp. Clin. Psychopharmacol.6,32–44 (1998).
  Medline CASGoogle Scholar
• 32  Stoops WW, Glaser PE, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and D-amphetamine in stimulant abusing humans. J. Psychopharmacol.18,534–543 (2004).
  Medline CASGoogle Scholar
• 33  Negus SS. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine and methadone. J. Pharmacol. Exp. Ther.317,711–723 (2006).
  Medline CASGoogle Scholar
• 34  Negus SS, Rice KC. Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacology34,899–911 (2009).
  Medline CASGoogle Scholar
• 35  Czoty PW, Martelle JL, Nader MA. Influence of abstinence and conditions of cocaine access on the reinforcing strength of cocaine in nonhuman primates. Drug Alcohol Depend.85,213–220 (2006).
  Medline CASGoogle Scholar
• 36  Banks ML, Negus SS. Effects of extended cocaine access and cocaine withdrawal on choice between cocaine and food in rhesus monkeys. Neuropsychopharmacology35,493–504 (2010).
  Medline CASGoogle Scholar
• 37  Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol.406,1–13 (2000).
  Medline CASGoogle Scholar
• 38  Johanson CE, Fischman MW. The pharmacology of cocaine related to its abuse. Pharmacol. Rev.41,3–52 (1989).
  Medline CASGoogle Scholar
• 39  Rothman RB, Glowa JR. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: focus on GBR 12909. Mol. Neurobiol.11,1–19 (1995).
  Medline CASGoogle Scholar
• 40  Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science237(4819),1219–1223 (1987).▪ This seminal preclinical study definitively demonstrated that the ability of cocaine to block dopamine reuptake is crucial to its abuse-related effects.
  Medline CASGoogle Scholar
• 41  Rothman RB, Baumann MH, Dersch CM et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse39,32–41 (2001).
  Medline CASGoogle Scholar
• 42  Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci.14(7),299–302 (1991).
  Medline CASGoogle Scholar
• 43  Witkin JM. Pharmacotherapy of cocaine abuse: preclinical development. Neurosci. Biobehav. Rev.18,121–142 (1994).
  Medline CASGoogle Scholar
• 44  Woolverton WL, Johnson KM. Neurobiology of cocaine abuse. Trends Pharmacol. Sci.13,193–200 (1992).
  Medline CASGoogle Scholar
• 45  Holmes VF. Medical use of psychostimulants: an overview. Int. J. Psychiatry Med.25(1),1–19 (1995).
  Medline CASGoogle Scholar
• 46  Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention/deficit hyperactivity disorder: a review. J. Clin. Psychopharmacol.15(4),270–279 (1995).
  Medline CASGoogle Scholar
• 47  Gatley SJ, Volkow ND, Gifford AN et al. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology146(1),93–100 (1999).
  Medline CASGoogle Scholar
• 48  Volkow ND, Fowler JS, Gatley JS et al. Comparable changes in synaptic dopamine induced by methylphenidate and cocaine in the baboon brain. Synapse31,59–66 (1999).
  Medline CASGoogle Scholar
• 49  Volkow ND, Wang GJ, Fowler JS et al. Methylphenidate and cocaine have similar in vivo potency to block the dopamine transporters in the human brain. Life Sci.65,7–12 (1999).
  Google Scholar
• 50  Volkow ND, Ding YS, Fowler JS et al. Is methylphenidate like cocaine?. Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry52,456–463 (1995).
  Medline CASGoogle Scholar
• 51  Bergman J, Madras BK, Johnson SE, Spealman RD. Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J. Pharmacol. Exp. Ther.251(1),150–155 (1989).
  Medline CASGoogle Scholar
• 52  Greenwald MK, Lundahl LH, Steinmiller CL. Sustained release D-amphetamine reduces cocaine but not ‘speedball’-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers. Neuropsychopharmacology35(13),2624–2637 (2010).
  Medline CASGoogle Scholar
• 53  Stoops WW, Glaser PE, Rush CR. Reinforcing, subject-rated, and physiological effects of intranasal methylphenidate in humans: a dose–response analysis. Drug Alcohol Depend.71,179–186 (2003).
  Medline CASGoogle Scholar
• 54  Rush CR, Baker RW. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp. Clin. Psychopharmacol.9(1),59–73 (2001).
  Medline CASGoogle Scholar
• 55  Wood DM, Emmett-Oglesby MW. Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology95,364–368 (1988).
  Medline CASGoogle Scholar
• 56  Fischman MW, Foltin RW. Cocaine self-administration research: implications for rational pharmacotherapy. In: Cocaine Abuse Research: Pharmacology, Behavior and Clinical Applications. Higgins ST, Katz JL (Eds). Academic Press, San Diego, CA, USA, 181–208 (1998).
  Google Scholar
• 57  Bigelow GE, Walsh SL. Evaluation of potential pharmacotherapies: response to cocaine challenge in the human laboratory. In: Cocaine Abuse Research: Pharmacology, Behavior and Clinical Applications. Higgins ST, Katz JL (Eds). Academic Press, San Diego, CA, USA, 209–238 (1998).
  Google Scholar
• 58  Glowa JR, Fantegrossi WE. Effects of dopaminergic drugs on food- and cocaine-maintained responding. IV: Continuous cocaine infusions. Drug Alcohol Depend.45,71–79 (1997).
  Medline CASGoogle Scholar
• 59  Hiranita T, Soto PL, Newman AH, Katz JL. Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J. Pharmacol. Exp. Ther.329(2),677–686 (2009).
  Medline CASGoogle Scholar
• 60  Negus SS. Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with D-amphetamine and flupenthixol. Neuropsychopharmacology28,919–931 (2003).
  MedlineGoogle Scholar
• 61  Skjoldager P, Winger G, Woods JH. Effects of GBR 12909 and cocaine on cocaine-maintained behavior in rhesus monkeys. Drug Alcohol Depend.33,31–39 (1993).
  Medline CASGoogle Scholar
• 62  Collins SL, Levin FR, Foltin RW, Kleber HD, Evans SM. Response to cocaine alone and in combination with methylphenidate in cocaine abusers with ADHD. Drug Alcohol Depend.82,158–167 (2006).
  Medline CASGoogle Scholar
• 63  Walsh SL, Haberny KA, Bigelow GE. Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology150,361–373 (2000).
  Medline CASGoogle Scholar
• 64  Winhusen T, Somoza E, Singal BM et al. Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol. Biochem. Behav.85,29–38 (2006).
  Medline CASGoogle Scholar
• 65  Oliveto AH, Rosen MI, Woods SW, Kosten TR. Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans. J. Pharmacol. Exp. Ther.272,231–241 (1995).
  Medline CASGoogle Scholar
• 66  Van Dyke C, Jatlow P, Ungerer J, Barash PG, Byck R. Oral cocaine: plasma concentrations and central effects. Science200,211–213 (1978).
  Medline CASGoogle Scholar
• 67  Johanson CE, Lundahl LH, Schubiner H. Effects of oral cocaine on intravenous cocaine discrimination in humans. Exp. Clin. Psychopharmacol.15(3),219–227 (2007).
  Medline CASGoogle Scholar
• 68  Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. J. Clin. Psychopharmacol.17(6),485–488 (1997).
  Medline CASGoogle Scholar
• 69  Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend.87(1),20–29 (2007).
  Medline CASGoogle Scholar
• 70  Schubiner H, Saules KK, Arfken CL et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp. Clin. Psychopharmacol.10(3),286–294 (2002).
  Medline CASGoogle Scholar
• 71  Fischman MW, Johanson CE. Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers. Behav. Pharmacol.9,479–498 (1998).
  Medline CASGoogle Scholar
• 72  Perkins KA, Lerman C, Stitzer M et al. Development of procedures for early screening of smoking cessation medications in humans. Clin. Pharmacol. Ther.84,216–221 (2008).
  Medline CASGoogle Scholar
• 73  Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Ann. Rev. Pharmacol. Toxicol.33,639–677 (1993).
  Medline CASGoogle Scholar
• 74  Carroll ME, Lac ST. Acquisition of i.v. amphetamine and cocaine self-administration in rats as a function of dose. Psychopharmacology129,206–214 (1997).
  Medline CASGoogle Scholar
• 75  Gasior M, Bergman J, Kallman MJ, Paronis CA. Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology30,758–764 (2005).
  Medline CASGoogle Scholar
• 76  Richardson NR, Roberts DCS. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J. Neurosci. Methods66,1–11 (1996).
  Medline CASGoogle Scholar
• 77  Shannon HE, Risner ME. Comparison of behavior maintained by intravenous cocaine and D-amphetamine in dogs. J. Pharmacol. Exp. Ther.229,422–432 (1984).
  Medline CASGoogle Scholar
• 78  Woolverton WL, Hecht GS, Agoston GE, Katz JL, Newman AH. Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys. Psychopharmacology154,375–382 (2001).
  Medline CASGoogle Scholar
• 79  Hodos W. Progressive ratio as a measure of reward strength. Science134,943–944 (1961).
  Medline CASGoogle Scholar
• 80  Johanson CE, Lundahl LH, Lockhart N, Schubiner H. Intravenous cocaine discrimination in humans. Exp. Clin. Psychopharmacol.14(2),99–108 (2006).
  Medline CASGoogle Scholar
• 81  Kamien JB, Woolverton WL. A pharmacological analysis of the discriminative stimulus properties of D-amphetamine in rhesus monkeys. J. Pharmacol. Exp. Ther.248,938–946 (1989).
  Medline CASGoogle Scholar
• 82  Li SM, Campbell BL, Katz JL. Interactions of cocaine with dopamine uptake inhibitors or dopamine releasers in rats discriminating cocaine. J. Pharmacol. Exp. Ther.317(3),1088–1096 (2006).
  Medline CASGoogle Scholar
• 83  Oliveto AH, McCance-Katz E, Singha A, Hameedi F, Kosten TR. Effects of D-amphetamine and caffeine in humans under a cocaine discrimination procedure. Behav. Pharmacol.9,207–217 (1998).
  Medline CASGoogle Scholar
• 84  Barrett AC, Miller JR, Dohrmann JM, Caine SB. Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology47(Suppl. 1),256–273 (2004).
  Medline CASGoogle Scholar
• 85  Deroche-Gamonet V, Darnaudery M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV. Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology161(4),387–395 (2002).
  Medline CASGoogle Scholar
• 86  Chiodo KA, Roberts DC. Decreased reinforcing effects of cocaine following 2 weeks of continuous D-amphetamine treatment in rats. Psychopharmacology206,447–456 (2009).
  Medline CASGoogle Scholar
• 87  Chiodo KA, Lack CM, Roberts DC. Cocaine self-administration reinforced on a progressive ratio schedule decreases with continuous D-amphetamine treatment in rats. Psychopharmacology200,465–473 (2008).
  Medline CASGoogle Scholar
• 88  Czoty PW, Martelle JL, Carroll FI, Nader MA. Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates. Pharmacol. Biochem. Behav.96(3),274–278 (2010).
  Medline CASGoogle Scholar
• 89  Czoty PW, Gould RW, Martelle JL, Nader MA. Prolonged attenuation of the reinforcing strength of cocaine by chronic D-amphetamine in rhesus monkeys. Neuropsychopharmacology36(2),539–547 (2011).
  Medline CASGoogle Scholar
• 90  Negus SS, Mello NK. Effects of chronic D-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology167,324–332 (2003a).
  Medline CASGoogle Scholar
• 91  Negus SS, Mello NK. Effects of chronic D-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend.70,39–52 (2003b).
  Medline CASGoogle Scholar
• 92  Negus SS, Mello NK, Blough BE, Baumann MH, Rothman RB. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate ‘agonist’ medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther.320,627–636 (2007).▪▪ This preclinical research demonstrated how potential agonist-replacement medications for cocaine use disorders with varying selectivity for different monoamines produce distinct changes in cocaine and food self-administration.
  Medline CASGoogle Scholar
• 93  Rush CR, Stoops WW, Sevak RJ, Hays LR. Cocaine choice in humans during D-amphetamine maintenance. J. Clin. Psychopharmacol.30(2),152–159 (2010).▪▪ This study was the first to demonstrate that maintenance on D-amphetamine attenuates the reinforcing effects of cocaine in the human laboratory.
  Medline CASGoogle Scholar
• 94  Rush CR, Stoops WW, Hays LR. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend.99,261–271 (2009).
  Medline CASGoogle Scholar
• 95  Griffiths RR, Troisi JR, Silverman K, Mumford GK. Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav. Pharmacol.4(1),3–13 (1993).
  Medline CASGoogle Scholar
• 96  Griffiths RR, Rush CR, Puhala KA. Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Exp. Clin. Psychopharmacol.4,97–106 (1996).
  Google Scholar
• 97  Grabowski J, Rhoades H, Schmitz J et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol.21(5),522–526 (2001).
  Medline CASGoogle Scholar
• 98  Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction98,1137–1141 (2003).
  MedlineGoogle Scholar
• 99  Higgins ST, Delaney DD, Budney AJ et al. A behavioral approach to achieving initial cocaine abstinence. Am. J. Psychiatry148(9),1218–1224 (1991).▪ This clinical study showed that a treatment grounded in operant theory (i.e., abstinence reinforcement) is more effective for reducing cocaine use than more traditional methods (i.e., a 12-step program).
  Medline CASGoogle Scholar
• 100  Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann. Pharmacother.35(12),1608–1613 (2001).
  Medline CASGoogle Scholar
• 101  Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int. J. Chron. Obstruct. Pulmon. Dis.3,45–53 (2008).
  Medline CASGoogle Scholar
• 102  Bredeloux P, Dubuc I, Costentin J. Comparisons between bupropion and dexamphetamine in a range of in vivo tests exploring dopaminergic transmission. Br. J. Pharmacol.150,711–719 (2007).
  Medline CASGoogle Scholar
• 103  Nomikos GG, Damsma G, Wenkstern D, Fibiger HC. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology2(4),273–279 (1989).
  Medline CASGoogle Scholar
• 104  Kleven MS, Anthony EW, Woolverton WL. Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther.254(1),312–317 (1990).
  Medline CASGoogle Scholar
• 105  Griffith JD, Carranza J, Griffith C, Miller LL. Bupropion: clinical assay for amphetamine-like abuse potential. J. Clin. Psychiatry44(5 Pt 2),206–208 (1983).
  Medline CASGoogle Scholar
• 106  Miller L, Griffith J. A comparison of bupropion, dextroamphetamine and placebo in mixed-substance abusers. Psychopharmacology80(3),199–205 (1983).
  Medline CASGoogle Scholar
• 107  Peck AW, Bye CE, Clubley M, Henson T, Riddington C. A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br. J. Clin. Pharmacol.7(5),469–478 (1979).
  Medline CASGoogle Scholar
• 108  Oliveto A, McCance-Katz FE, Singha A, Petrakis I, Hameedi F, Kosten TR. Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug Alcohol Depend.63(2),155–167 (2001).
  Medline CASGoogle Scholar
• 109  Stoops WW, Lile JA, Hays LR, Glaser PE, Rush CR. Influence of acute bupropion pretreatment on the effects of intranasal cocaine. Addiction (2012) (In press).
  MedlineGoogle Scholar
• 110  Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend.81(2),137–148 (2006).
  Medline CASGoogle Scholar
• 111  Margolin A, Kosten T, Petrakis I, Avants SK. Bupropion reduces cocaine abuse in methadone-maintained patients. Arch. Gen. Psychiatry48(1),87 (1991).
  Medline CASGoogle Scholar
• 112  Margolin A, Kosten TR, Avants SK et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend.40(2),125–131 (1995).
  Medline CASGoogle Scholar
• 113  Poling J, Oliveto A, Petry N et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch. Gen. Psychiatry63(2),219–228 (2006).
  Medline CASGoogle Scholar
• 114  Shoptaw S, Heinzerling KG, Rotheram-Fuller E et al. Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. J. Addict. Dis.27,13–23 (2008).
  MedlineGoogle Scholar
• 115  Broughton RJ, Fleming JA, George CF et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology49,444–451 (1997).
  Medline CASGoogle Scholar
• 116  Miller JL. Modafinil approved for narcolepsy. Am. J. Health Syst. Pharm.56(4),304 (1999).
  MedlineGoogle Scholar
• 117  Moldofsky H, Broughton RJ, Hill JD. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med.1,109–116 (2000).
  Medline CASGoogle Scholar
• 118  Teitelman E. Modafinil for narcolepsy. Am. J. Psychiatry158,970–971 (2001).
  Medline CASGoogle Scholar
• 119  Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL. Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology210(3),439–448 (2010).
  Medline CASGoogle Scholar
• 120  Madras BK, Xie Z, Lin Z et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J. Pharmacol. Exp. Ther.319(2),561–569 (2006).
  Medline CASGoogle Scholar
• 121  Volkow ND, Fowler JS, Logan J et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA301,1148–1154 (2009).
  Medline CASGoogle Scholar
• 122  Zolkowska D, Jain R, Rothman RB et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J. Pharmacol. Exp. Ther.329,738–746 (2009).
  Medline CASGoogle Scholar
• 123  Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur. J. Pharmacol.568(1–3),112–123 (2007).
  Medline CASGoogle Scholar
• 124  Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology126(4),286–292 (1996).
  Medline CASGoogle Scholar
• 125  Newman JL, Negus SS, Lozama A, Prisinzano TE, Mello NK. Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp. Clin. Psychopharmacol.18(5),395–408 (2010).
  Medline CASGoogle Scholar
• 126  Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF. Acute behavioral and physiological effects of modafinil in drug abusers. Behav. Pharmacol.13(2),105–115 (2002).
  Medline CASGoogle Scholar
• 127  Rush CR, Kelly TH, Hays LR, Wooten AF. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend.67(3),311–322 (2002a).
  Medline CASGoogle Scholar
• 128  Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J. Psychopharmacol.14(1),53–60 (2000).
  Medline CASGoogle Scholar
• 129  Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin. Neuropharmacol.23(3),149–156 (2000).
  Medline CASGoogle Scholar
• 130  Malcolm R, Book SW, Moak D, DeVane L, Czepowicz V. Clinical applications of modafinil in stimulant abusers: low abuse potential. Am. J. Addict.11,247–249 (2002).
  MedlineGoogle Scholar
• 131  Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical and post-marketing surveillance – a review of abuse liability issues. Ann. Clin. Psychiatry16(2),101–109 (2004).
  MedlineGoogle Scholar
• 132  Vosburg SK, Hart CL, Haney M, Rubin E, Foltin RW. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend.106,233–236 (2010).
  Medline CASGoogle Scholar
• 133  Dackis CA, Lynch KG, Yu E et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend.70(1),29–37 (2003).
  Medline CASGoogle Scholar
• 134  Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology33(4),761–768 (2008).
  Medline CASGoogle Scholar
• 135  Malcolm R, Swayngim K, Donovan JL et al. Modafinil and cocaine interactions. Am. J. Drug Alcohol Abuse32(4),577–587 (2006).
  MedlineGoogle Scholar
• 136  Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O’Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology30(1),205–211 (2005).
  Medline CASGoogle Scholar
• 137  Anderson AL, Reid MS, Li SH et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend.104(1–2),133–139 (2009).
  Medline CASGoogle Scholar
• 138  Carroll FI, Howell LL, Kuhar MJ. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem.42,2721–2736 (1999).
  Medline CASGoogle Scholar
• 139  Carroll FI, Pawlush N, Kuhar MJ, Pollard GT, Howard JL. Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3β-(substituted phenyl)-2β-(3´-substituted isoxazol-5-yl)tropanes. J. Med. Chem.47,296–302 (2004).
  Medline CASGoogle Scholar
• 140  Carroll FI, Runyon SP, Abraham P et al. Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers. J. Med. Chem.47,6401–6409 (2004).
  Medline CASGoogle Scholar
• 141  Carroll FI, Howard JL, Howell LL, Fox BS, Kuhar MJ. Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J.8,E196–E203 (2006).
  Medline CASGoogle Scholar
• 142  Carroll FI, Fox BS, Kuhar MJ, Howard JL, Pollard GT, Schenk S. Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration. Eur. J. Pharmacol.553,149–156 (2006).
  Medline CASGoogle Scholar
• 143  Kimmel HL, O’Connor JA, Carroll FI, Howell LL. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol. Biochem. Behav.86(1),45–54 (2007).
  Medline CASGoogle Scholar
• 144  Kimmel HL, Negus SS, Wilcox KM et al. Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol. Biochem. Behav.90(3),453–462 (2008).
  Medline CASGoogle Scholar
• 145  Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL. Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J. Pharmacol. Exp. Ther.320(2),757–765 (2007).
  Medline CASGoogle Scholar
• 146  Haile CN, Zhang XY, Carroll FI, Kosten TA. Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter. Brain Res.1055(1–2),186–195 (2005).
  Medline CASGoogle Scholar
• 147  Czoty PW, Ginsburg BC, Howell LL. Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J. Pharmacol. Exp. Ther.300(3),831–837 (2002).
  Medline CASGoogle Scholar
• 148  Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J. Pharmacol. Exp. Ther.313,848–854 (2005).
  Medline CASGoogle Scholar
• 149  Rothman RB, Blough BE, Woolverton WL et al. Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J. Pharmacol. Exp. Ther.313,1361–1369 (2005).
  Medline CASGoogle Scholar
• 150  Negus SS, Baumann MH, Rothman RB, Mello NK, Blough BE. Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine. J. Pharmacol. Exp. Ther.329,272–281 (2009).
  Medline CASGoogle Scholar
• 151  Abreu ME, Bigelow GE, Fleisher L, Walsh SL. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology154(1),76–84 (2001).
  Medline CASGoogle Scholar
• 152  Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp. Clin. Psychopharmacol.6(4),367–374 (1998).
  Medline CASGoogle Scholar
• 153  Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, Phase I study in healthy adult volunteers. Clin. Drug. Investig.28,745–755 (2008).
  Medline CASGoogle Scholar
• 154  Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr. Med. Res. Opin24,33–40 (2008).
  Medline CASGoogle Scholar
• 155  Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J. Psychopharmacol.23,410–418 (2009).
  Medline CASGoogle Scholar
• 156  Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J. Psychopharmacol.23,419–427 (2009).
  Medline CASGoogle Scholar
• 157  Rothman RB, Dersch CM, Carroll FI, Ananthan S. Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding. Synapse43,268–274 (2002).
  Medline CASGoogle Scholar
• 158  de la Garza R, Johanson CE. Discriminative stimulus properties of intragastrically administered D-amphetamine and pentobarbital in rhesus monkeys. J. Pharmacol. Exp. Ther.243(3),955–962 (1987).
  Medline CASGoogle Scholar
• 159  Evans SM, Johanson CE. Amphetamine-like effects of anorectics and related compounds in pigeons. J. Pharmacol. Exp. Ther.241,817–825 (1987).
  Medline CASGoogle Scholar
• 160  Corwin RL, Woolverton WL, Schuster CR, Johanson CE. Anorectics: effects on food intake and self-administration in rhesus monkeys. Alcohol Drug Res.7,351–361 (1987).
  Medline CASGoogle Scholar
• 161  Griffiths RR, Brady JV, Bradford LD. Predicting the abuse liability of drugs with animal drug self-administration procedures: psychomotor stimulants and hallucinogens. In: Advances in Behavioral Pharmacology, Volume 2. Thompson T, Dews PB (Eds). Academic Press, NY, USA 163–208 (1979).
  Google Scholar
• 162  Bramble D. Psychostimulants and psychiatrists: the Trent Adult Psychiatry Psychostimulant Survey. J. Psychopharmacol.14,67–69 (2000).
  Medline CASGoogle Scholar
• 163  Klein RG. The role of methylphenidate in psychiatry. Arch. Gen. Psychiatry52,429–433 (1995).
  Medline CASGoogle Scholar
• 164  Goeders NE, McNulty MA, Mirkis S, McAllister KH. Chlordiazepoxide alters intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav.33,859–866 (1989).
  Medline CASGoogle Scholar
• 165  Goeders NE, McNulty MA, Guerin GF. Effects of alprazolam on intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav.44,471–474 (1993).
  Medline CASGoogle Scholar
• 166  Goeders NE, Guerin GF. Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol. Biochem. Behav.91,181–189 (2008).
  Medline CASGoogle Scholar
• 167  Goeders NE, Clampitt DM. Potential role for the hypothalamo-pituitary-adrenal axis in the conditioned reinforcer-induced reinstatement of extinguished cocaine seeking in rats. Psychopharmacology161,222–232 (2002).
  Medline CASGoogle Scholar
• 168  Keim KL, Sigg EB. Plasma corticosterone and brain catecholamines in stress: effect of psychotropic drugs. Pharmacol. Biochem. Behav.6,79–85 (1977).
  Medline CASGoogle Scholar
• 169  Yang XM, Gorman AL, Dunn AJ, Goeders, NE. Anxiogenic effects of acute and chronic cocaine administration: neurochemical and behavioral studies. Pharmacol. Biochem. Behav.41,643–650 (1992).
  Medline CASGoogle Scholar
• 170  Goeders NE, Guerin GF. Effects of surgical and pharmacological adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration in rats. Brain Res.722,145–152 (1996).
  Medline CASGoogle Scholar
• 171  Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR. Subjective and physiological effects of acute intranasal methamphetamine during extended-release alprazolam maintenance. Drug Alcohol Depend.119(3),187–193 (2011).
  Medline CASGoogle Scholar
• 172  Mumford GK, Evans SM, Fleishaker, JC, Griffiths, RR. Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol. Ther.57,356–365 (1995).
  Medline CASGoogle Scholar
• 173  Mumford GK, Rush CR, Griffiths, RR. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J. Pharmacol. Exp. Ther.272,570–580 (1995).
  Medline CASGoogle Scholar
• 174  Rush CR, Griffiths RR. Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Exp. Clin. Psychopharmacol.5,28–38 (1997).
  Medline CASGoogle Scholar
• 175  Rush CR, Higgins ST, Bickel WK, Hughes JR. Abuse liability of alprazolam relative to other commonly used benzodiazepines: a review. Neurosci. Biobehav. Rev.17,277–285 (1993).
  Medline CASGoogle Scholar
• 176  Kablinger AS, Lindner MA, Casso S et al. Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study. J. Psychopharmacol. (2011) (In Press).
  Google Scholar